Kazia Therapeutics (KZIA) Stock Price, News & Analysis

Company Overview

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Key Stats

• Today's Range: $3.30 to $3.64
• 50-Day Range: $3.09 to $4.95
• 52-Week Range: $2.86 to $79.00
• Volume: 12,132 shs
• Average Volume: 175,129 shs
• Market Capitalization: $3.61 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $57.50
• Consensus Rating: Buy

KZIA Stock Analysis - Frequently Asked Questions

How have KZIA shares performed this year?

Kazia Therapeutics' stock was trading at $8.85 at the start of the year. Since then, KZIA shares have decreased by 59.5% and is now trading at $3.58.
View the best growth stocks for 2025 here.

When did Kazia Therapeutics' stock split?

Kazia Therapeutics shares reverse split on the morning of Monday, October 28th 2024. The 1-10 reverse split was announced on Tuesday, October 15th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, October 25th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Kazia Therapeutics?

Shares of KZIA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Kazia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Kazia Therapeutics investors own include NVIDIA (NVDA), Adobe (ADBE), Broadcom (AVGO), Arista Networks (ANET), ServiceNow (NOW), Meta Platforms (META) and Advanced Micro Devices (AMD).

Company Calendar

• Today: 5/24/2025
• Fiscal Year End: 6/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:KZIA
• Previous Symbol: ASX:KZA
• CIK: 1075880
• Web: www.kaziatherapeutics.com
• Phone: (129) 472-4101
• Fax: 61-2-9476-0388
• Employees: 12
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $57.50
• High Stock Price Target: $100.00
• Low Stock Price Target: $15.00
• Potential Upside/Downside: +1,506.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.24
• Quick Ratio: 0.24

Sales & Book Value

• Annual Sales: $2.31 million
• Price / Sales: 1.56
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.97) per share
• Price / Book: -1.82

Miscellaneous

• Outstanding Shares: 1,007,000
• Free Float: 4,986,000
• Market Cap: $3.61 million
• Optionable: Optionable
• Beta: 2.49